We are live on ! Find out more
SRNE

Sorrento Therapeutics, Inc.
SRNE

Delisted

SRNE was delisted on the 22nd of February, 2023.

Back to rankings

9 hedge funds and large institutions have $26.1K invested in Sorrento Therapeutics, Inc. in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

74% less funds holding

Funds holding: 34 → 9 (-25)

96% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 26

98% less capital invested

Capital invested by funds: $1.58M → $26.1K (-$1.56M)

Holders
9
Holders Change
-25
Holders Change %
-73.53%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
–
Closed
26
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SW
SlateStone Wealth
Florida
+$3.36K
2
HNB
Huntington National Bank
Ohio
+$716

Top Sellers

Rank Fund Capital Flow
1
PP
Paloma Partners
Connecticut
-$1.36M
2
OCM
Oaktree Capital Management
California
-$48.2K
3
OFA
Oaktree Fund Advisors
California
-$23.8K
4
CGA
Crescent Grove Advisors
Illinois
-$21.6K
5
LCM
Lattice Capital Management
Washington
-$18.6K

SRNE Hedge Fund Activity: Q2 2023 in Review

9 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q2 2023, worth a combined $26.1K — down 98% from $1.58M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of SRNE and 1 opened new positions — a net loss of 25 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was SlateStone Wealth, adding an estimated $3.36K. The largest seller was Paloma Partners, exiting entirely with an estimated $1.36M sold.

  • 9 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q2 2023, down from 34 in Q1 2023.
  • Funds reported $26.1K of Sorrento Therapeutics, Inc. stock for Q2 2023, down 98% quarter-over-quarter.
  • 1 fund opened new Sorrento Therapeutics, Inc. positions in Q2 2023 and 26 closed out, a net change of -25 holders.
  • The largest Sorrento Therapeutics, Inc. buyer in Q2 2023 was SlateStone Wealth, an estimated $3.36K added.
  • The largest Sorrento Therapeutics, Inc. seller in Q2 2023 was Paloma Partners, an estimated $1.36M sold.

Based on aggregated 13F filings for Q2 2023.